Allogene Therapeutics (ALLO) Other Gross PP&E Adjustments (2018 - 2026)

Allogene Therapeutics' Other Gross PP&E Adjustments history runs 9 years deep, the most recent figure standing at $106.6 million for Q1 2026.

• In Q1 2026, Other Gross PP&E Adjustments rose 1.96% year-over-year to $106.6 million; the TTM figure through Mar 2026 stood at $106.6 million (up 1.96% YoY), while the FY2025 annual figure was $79.5 million, down 2.44% from the prior year.
• Other Gross PP&E Adjustments came in at $106.6 million for Q1 2026 at Allogene Therapeutics, up from $79.5 million in the prior quarter.
• In the past five years, Other Gross PP&E Adjustments ranged from a high of $140.9 million in Q2 2024 to a low of $40.4 million in Q4 2022.
• A 5-year average of $86.5 million and a median of $81.5 million in 2024 frame the typical range for Other Gross PP&E Adjustments.
• Across the five-year window, Other Gross PP&E Adjustments plunged 45.13% in 2022 and jumped 101.04% in 2024, its largest moves.
• Allogene Therapeutics' Other Gross PP&E Adjustments stood at $40.4 million in 2022, then jumped by 52.25% to $61.5 million in 2023, then soared by 32.53% to $81.5 million in 2024, then decreased by 2.44% to $79.5 million in 2025, then surged by 34.04% to $106.6 million in 2026.
• According to Business Quant data, Other Gross PP&E Adjustments over the past three periods registered $106.6 million, $79.5 million, and $104.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison